Kristin M. Bompiani, Ph.D.

2012 Genetics and Genomics Duke University, Durham, NC 
Biochemistry, Molecular Biology
"Kristin Bompiani"


Sign in to add mentor
Bruce A. Sullenger grad student 2012 Duke
 (Development of RNA Aptamers and Antidotes as Antithrombotic Therapeutics.)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Gunaratne R, Kumar S, Frederiksen JW, et al. (2018) Combination of aptamer and drug for reversible anticoagulation in cardiopulmonary bypass. Nature Biotechnology
Kahsai AW, Wisler JW, Lee J, et al. (2016) Conformationally selective RNA aptamers allosterically modulate the β2-adrenoceptor. Nature Chemical Biology
Bompiani KM, Tsai CY, Achatz FP, et al. (2016) Copper transporters and chaperones CTR1, CTR2, ATOX1, and CCS as determinants of cisplatin sensitivity. Metallomics : Integrated Biometal Science. 8: 951-62
Soule EE, Bompiani KM, Woodruff RS, et al. (2015) Targeting Two Coagulation Cascade Proteases with a Bivalent Aptamer Yields a Potent and Antidote-Controllable Anticoagulant. Nucleic Acid Therapeutics
Bompiani KM, Dickerson TJ. (2014) High-throughput screening technologies for botulinum neurotoxins. Current Topics in Medicinal Chemistry. 14: 2062-80
Bompiani KM, Lohrmann JL, Pitoc GA, et al. (2014) Probing the coagulation pathway with aptamers identifies combinations that synergistically inhibit blood clot formation. Chemistry & Biology. 21: 935-44
Caglič D, Krutein MC, Bompiani KM, et al. (2014) Identification of clinically viable quinolinol inhibitors of botulinum neurotoxin A light chain. Journal of Medicinal Chemistry. 57: 669-76
Cagli? D, Bompiani KM, Krutein MC, et al. (2013) A high-throughput-compatible FRET-based platform for identification and characterization of botulinum neurotoxin light chain modulators. Journal of Visualized Experiments : Jove. 50908
Bompiani KM, Monroe DM, Church FC, et al. (2012) A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity. Journal of Thrombosis and Haemostasis : Jth. 10: 870-80
Bompiani KM, Woodruff RS, Becker RC, et al. (2012) Antidote control of aptamer therapeutics: the road to a safer class of drug agents. Current Pharmaceutical Biotechnology. 13: 1924-34
See more...